Rightway Raises $155M Series E as Employers Challenge Traditional Pharmacy Benefits

Rightway has raised $155 million in Series E financing to expand its pharmacy-benefit management and healthcare-navigation platform.

Francisco Partners led the round. Existing investors Thrive Capital and Khosla Ventures also participated. Rightway did not disclose a valuation in its September 24 announcement.

Rightway's Series E at a glance

• Round: Series E
• Amount: $155 million
• Lead investor: Francisco Partners
• Other investors: Thrive Capital and Khosla Ventures
• Valuation: Undisclosed
• Headquarters: New York
• Use of proceeds: AI capabilities and technology supporting pharmacy-benefit management

Rightway says it now works with 45 Fortune 500 companies, or nearly 10% of the index. That customer count is company-reported.

Rightway's investment thesis is pharmacy-cost alignment

Pharmacy-benefit managers sit between employers, health plans, pharmacies and drugmakers. The traditional model has faced scrutiny because rebates, spread pricing and administrative fees can make the real cost of a prescription difficult for employers to see.

Rightway's pitch is that its economics are aligned with the plan sponsor. The company says it passes through rebates, embeds pharmacists in the member experience and uses technology to guide patients toward appropriate lower-cost options.

Its SureSpend model includes a ceiling on total pharmacy spending and a zero-markup structure for categories that are often excluded from standard guarantees, including GLP-1 drugs and rare, high-cost medicines.

Those product claims come from Rightway's announcement. Employers still need to evaluate the contract-level definitions, exclusions and savings methodology behind any guarantee.

Baba’s October 2026 $40M Series A offers a care-coordination comparison focused on Medicare and Medicaid. Its insurer billing and human delivery costs differ from Rightway’s employer-focused pharmacy-benefit model.

Why a $155M Series E now

Drug spending is becoming a larger and less predictable part of employee-benefit budgets. GLP-1 adoption, specialty medicines and rare-disease therapies can create sharp cost swings even for large employers.

That gives technology-enabled pharmacy managers a large market, but it also puts them in direct competition with deeply integrated incumbents. Rightway must prove that a more transparent model can maintain clinical quality, negotiate effectively and scale across complex pharmacy networks.

The Series E will fund additional AI capabilities and the software supporting Rightway's pharmacy-benefit platform. The useful diligence question is not simply whether AI is present. It is whether automation improves drug selection, member support and claims administration without weakening clinical oversight.

What competitors covered—and what matters more

Most early coverage repeated the financing announcement, the investor list and Rightway's Fortune 500 customer count. The more important angle is the business-model challenge to traditional pharmacy-benefit economics.

A meaningful follow-up would test three items:

1. Whether reported savings are measured against a transparent, comparable benchmark.
2. How the company handles expensive therapies that fall outside conventional guarantees.
3. Whether its care-navigation product improves adherence and outcomes rather than only lowering gross pharmacy spend.

Rightway has now raised a late-stage round large enough to support national expansion. The next proof point is whether its aligned model can keep working as the company serves more employers, members and high-cost drug categories.